Form 8-K - Current report:
SEC Accession No. 0001104659-22-067717
Filing Date
2022-06-02
Accepted
2022-06-02 17:21:36
Documents
12
Period of Report
2022-06-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2217582d1_8k.htm   iXBRL 8-K 24690
  Complete submission text file 0001104659-22-067717.txt   197322

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20220601.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20220601_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20220601_pre.xml EX-101.PRE 22599
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2217582d1_8k_htm.xml XML 3614
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 22992016
SIC: 2836 Biological Products, (No Diagnostic Substances)